Tango Therapeutics named three senior executives to support the late-stage push of vopimetostat, its PRMT5 inhibitor being advanced toward a first potential regulatory filing in pancreatic cancer.
Matthew Gall was appointed chief financial officer effective April 15, replacing Daniella Beckman. Gall previously served as CFO at Kalaris Therapeutics and iTeos Therapeutics and held finance, business development and corporate strategy roles at Sarepta Therapeutics, Celgene and Gilead Sciences.
Yen-Ching Chua was named chief development operations officer effective June 1. In that role, she will oversee clinical operations, data management, quality, clinical compliance and clinical sourcing. Her background includes development operations leadership at Novocure, Debiopharm International, Morphosys and Novartis.
Janice Kapty, PhD, was appointed senior vice president of corporate strategy and project leadership effective April 15. She will oversee portfolio strategy, the project management organization and project leadership for vopimetostat and portfolio therapies, including TNG456. Kapty previously led drug development teams at Arvinas, Morphosys, Constellation Pharmaceuticals, Bristol Myers Squibb and Celgene.
The leadership changes come as Tango said it expects key clinical data this year, including initial data from its combination trial with Revolution Medicines’ RAS(ON) inhibitors. The company said the appointments are intended to strengthen finance, development operations and project leadership as it moves vopimetostat through late-stage development and toward potential commercialization. The market has reacted to these announcements by moving the company's shares -4.88% to a price of $19.86. For the full picture, make sure to review Tango Therapeutics's 8-K report.
